MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Kymera Therapeutics Inc

Închisă

SectorSănătate

26.35 4.48

Rezumat

Modificarea prețului

24h

Curent

Minim

24.28

Maxim

26.79

Indicatori cheie

By Trading Economics

Venit

-8.3M

-71M

Vânzări

3.7M

7.4M

EPS

-0.89

Marjă de profit

-956.884

Angajați

188

EBITDA

-8.3M

-69M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+114.94% upside

Dividende

By Dow Jones

Următoarele câștiguri

2 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-363M

1.9B

Deschiderea anterioară

21.87

Închiderea anterioară

26.35

Sentimentul știrilor

By Acuity

50%

50%

180 / 386 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Kymera Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

1 nov. 2024, 03:00 UTC

Top știri

U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners -- WSJ

9 iul. 2024, 09:05 UTC

Top știri

These Stocks Are Moving the Most Today: Tesla, Corning, BP, Intel, and More -- Barrons.com

Comparație

Modificare preț

Kymera Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

114.94% sus

Prognoză pe 12 luni

Medie 58.83 USD  114.94%

Maxim 97 USD

Minim 49 USD

În baza a 14 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruKymera Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

14 ratings

12

Cumpărare

2

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

N/A / 30.39Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Strong Bearish Evidence

Sentiment

By Acuity

180 / 386 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.